Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature

Nobumasa Ohara¹*, Michi Kobayashi¹,², Kazumasa Ohashi³, Ryo Ito³, Yohei Ikeda⁴, Gen Kawaguchi⁴, Yuichiro Yoneoka⁵, Go Hasegawa⁶ and Toshinori Takada³

Abstract

Introduction: Immune checkpoint inhibitors are a promising class of anticancer drugs. The clinical benefits afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events that affect multiple organs, and endocrine immune-related adverse events include thyroiditis and hypophysitis. Hypophysitis is less frequent and has a less severe clinical presentation in patients treated with other immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, than in those treated with ipilimumab. However, studies have described isolated adrenocorticotropic hormone deficiency cases associated with nivolumab, pembrolizumab, and atezolizumab therapy, most of which occurred during the course of immune checkpoint inhibitor therapy. We report a rare case of patient with isolated adrenocorticotropic hormone deficiency that occurred after nivolumab therapy.

Case presentation: A 69-year-old Japanese woman with advanced lung adenocarcinoma developed painless thyroiditis with transient elevations of serum thyroid hormones during 3 months of cancer treatment with nivolumab and began thyroid hormone replacement therapy for subsequent primary hypothyroidism. Four months after nivolumab therapy was discontinued, she developed isolated adrenocorticotropic hormone deficiency; corticosteroid replacement therapy relieved her secondary adrenal insufficiency symptoms, such as anorexia and fatigue. Human leukocyte antigen typing revealed the presence of DRB1*04:05-DQB1*04:01-DQA1*03:03 and DRB1*09:01-DQB1*03:03-DQA1*03:02 haplotypes, which increase susceptibility to autoimmune polyendocrine syndrome associated with thyroid and pituitary disorders in the Japanese population.

Conclusions: Our patient developed thyroiditis during cancer treatment with nivolumab and subsequently exhibited isolated adrenocorticotropic hormone deficiency 4 months after discontinuing the drug. Administration of nivolumab in combination with a genetic predisposition to polyglandular autoimmunity probably caused both the thyroiditis and hypophysitis, resulting in primary hypothyroidism and isolated adrenocorticotropic hormone deficiency, respectively, in our patient. The present case highlights the need for physicians to be aware that endocrine immune-related adverse events, including hypophysitis, can occur more than several months after discontinuing a drug.

Keywords: Human leukocyte antigen, Hydrocortisone, Isolated adrenocorticotropic hormone deficiency, Lung adenocarcinoma, Nivolumab, Thyroiditis

* Correspondence: oharan@med.niigata-u.ac.jp
¹Department of Endocrinology and Metabolism, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, 4132 Urasa, Minamiuonuma, Niigata 949-7302, Japan
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction

Immune checkpoint inhibitors (ICIs) are a promising new class of anticancer drugs that reactivate cytotoxic T cells which, in turn, destroy tumor cells [1]. Because ICIs generate dysimmune toxicities (autoimmunity) by creating an imbalance within the immune system, the clinical benefits afforded by ICIs can be accompanied by immune-related adverse events (IRAEs) that affect multiple organs, mainly the skin, gut, liver, lung, and endocrine tissues [2]. Common endocrine IRAEs include thyroiditis and hypophysitis, whereas uncommon IRAEs include adrenalitis and type 1 diabetes mellitus [3].

Compared with those treated with ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 monoclonal antibody, hypophysitis is less frequent and has a less severe clinical presentation in patients treated with other ICIs, such as nivolumab and pembrolizumab, which are anti-programmed cell death protein 1 (PD-1) monoclonal antibodies, and atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody [4–6]. However, studies have described isolated adrenocorticotropic hormone deficiency (IAD) cases associated with nivolumab, pembrolizumab, and atezolizumab therapy [7–22], most of which have occurred during the course of ICI therapy.

IAD is a pituitary disorder characterized by secondary adrenal insufficiency (AI) with low or absent cortisol production but normal secretion of pituitary hormones other than adrenocorticotropic hormone (ACTH) [23]. Patients with IAD typically present with anorexia, fatigue, and general weakness, but corticosteroid replacement therapy is effective for managing this disorder.

We report a case of a patient with advanced lung adenocarcinoma (LAC) who developed thyroiditis during nivolumab therapy and subsequently exhibited IAD 4 months after the discontinuation of nivolumab. We also review previously reported cases of nivolumab-related thyroiditis and IAD.

Case presentation

A 69-year-old Japanese woman who had been undergoing cancer treatment for advanced LAC was admitted to our hospital in January 2018 because of anorexia, fatigue, and general weakness. The patient had a maternal family history of esophageal cancer. The patient had been a housewife since her 20s, had never smoked cigarettes, and did not have a drinking habit. The patient's medical history was unremarkable until June 2016, when an abnormal x-ray shadow was found in her right lung. A computed tomographic (CT) scan revealed a tumor (3.1 cm) in the upper lobe of her right lung (Fig. 1a), right hilar and mediastinal lymph node swellings, and liver tumors. A transbronchoscopic biopsy from the lung tumor revealed LAC with vascular invasion (Fig. 2). IHC revealed no anaplastic lymphoma kinase rearrangement, and a genetic analysis of the cancer cells detected no epidermal growth factor receptor mutation. Whole-body technetium-99m methylene diphosphonate scintigraphy revealed multiple lesions at the thoracic and lumbar vertebrae, sternum, ilium, and right ischial bones. Brain magnetic resonance imaging (MRI) revealed tumors in the left temporal lobe and right cerebellar hemisphere (Fig. 1b). As a result, the patient was diagnosed with LAC with distant metastases to the brain, liver, and bones (cT2aN2M1b, stage IV) [24].
The patient underwent stereotactic radiation surgery (total, 22 Gy) for her metastatic brain tumors in July 2016. Thereafter, she received four courses of chemotherapy with intravenous cisplatin, pemetrexed, and bevacizumab from July 2016 to October 2016; this treatment regimen effectively controlled her advanced LAC with a Response Evaluation Criteria in Solid Tumors (RECIST) classification of partial response [25]. The patient subsequently received nine courses of maintenance chemotherapy with intravenous pemetrexed and bevacizumab from November 2016 to April 2017. CT scans performed in May 2017 revealed no progression of the primary LAC or metastatic brain and bone lesions, but they showed evidence of progression of the metastatic liver tumors.

Subsequently, the patient began second-line chemotherapy with intravenous nivolumab (133 mg [3 mg/kg] every 2 weeks) in May 2017 (Fig. 3). Thyroid function was routinely monitored in July 2017 after five courses of nivolumab therapy, and she showed high levels of serum free thyroxine (FT₄, 1.91 ng/dl) and low levels of thyroid-stimulating hormone (TSH, 0.04 μU/ml). The patient had no symptoms of thyrotoxicosis or exophthalmos but had mild and soft struma without any pain or fever. Ultrasonography revealed rough and mildly low echogenicity in a slightly enlarged thyroid gland without a tumor (Fig. 4a, b), and technetium-99m pertechnetate thyroid scintigraphy revealed a low thyroid uptake of 0.1% (reference range, 0.5–4%) in the entire thyroid gland (Fig. 4c). The patient had negative test results for TSH-binding inhibitory immunoglobulin (TBI), thyroglobulin autoantibody (TgAb), and thyroid peroxidase autoantibody (TPOAb). On the basis of these findings, she was diagnosed with painless thyroiditis induced by nivolumab and was closely followed without medication. The patient exhibited primary hypothyroidism (FT₄, 0.66 ng/dl; TSH, 11.41 μU/ml) in September 2017 and initiated thyroid hormone replacement therapy with oral levothyroxine (50 μg/day).

Fig. 2 Histopathological findings of biopsy specimen from the left lung tumor (July 2016). a, b Microscopic examination showing bronchial mucosal infiltration by poorly differentiated lung adenocarcinoma (a), and vascular invasion is seen (arrows) (b) (H&E staining). c, d The cytoplasm of the tumor cells was immunohistochemically positive for surfactant protein A (c), and the tumor cell nuclei were positive for thyroid transcription factor 1 (d). Ly Lymph duct, V Vein.
Because the CT scans performed after the sixth cycle of nivolumab revealed enlargements of the metastatic liver tumors, nivolumab therapy was discontinued in August 2017. The patient received three courses of third-line chemotherapy with docetaxel and ramucirumab beginning in September 2017, which effectively controlled her LAC (RECIST classification of partial response), but this treatment was terminated in October 2017 because of side effects, such as joint pain and rhabdomyolysis. The patient did not consent to continue anticancer drug therapy after considering the potential benefits and side effects, and she chose to receive best supportive care.

In November 2017, the patient’s body weight, blood pressure, and pulse rate were 45 kg, 121/67 mmHg, and 76 beats per minute, respectively. She had normal levels of serum electrolytes (sodium 140 mEq/L, potassium 4.3 mEq/L, and chloride 106 mEq/L). However, the
patient developed acute anorexia, fatigue, and general weakness in December 2017 and was admitted to the Department of Respiratory Medicine at our hospital in January 2018.

On admission, the patient had clear consciousness and did not complain of headache, abdominal pain, diarrhea, or joint and muscle pain. Her height, body weight, body temperature, blood pressure, and pulse rate were 153 cm, 38 kg, 36.9 °C, 90/54 mmHg, and 73 beats per minute, respectively. She had mild and soft goiter without pain. No heart murmur, chest rales, rash, vitiligo, skin pigmentation, or peripheral edema was detected. No paralysis, cerebellar ataxia, pyramidal or extrapyramidal tract symptoms, visual disturbance, hearing loss, dysarthria, or epileptic seizures were found. A blood analysis revealed hyponatremia (serum sodium 124 mEq/L); asymptomatic hypoglycemia (fasting plasma glucose 65 mg/dl); and low levels of immunoreactive insulin (< 0.2 μU/ml), ACTH (2.6 pg/ml), and cortisol (< 0.2 μg/dl) (Table 1). Because AI was suspected, oral levothyroxine was discontinued on day 2 of admission because hormone replacement therapy with thyroid hormone alone can exacerbate AI symptoms when hypothyroidism and AI coexist. The patient was referred to the Department of Endocrinology and Metabolism on day 5 of admission.

A rapid cosyntropin stimulation test suggested secondary AI (Table 2). Dynamic tests assessing the secretion of pituitary hormones showed the normal release of growth hormone (GH), TSH, and prolactin; age-appropriate release of luteinizing hormone and follicle-stimulating hormone; but no ACTH release following a corticotropin-releasing hormone load (Table 3). A GH-releasing peptide 2 loading test also showed no ACTH release, whereas GH release was sufficient (Table 4). These findings were indicative of IAD. A brain MRI study revealed slight atrophy of the anterior pituitary with a pituitary height of 2.2 mm (Fig. 5).

The patient had negative test results for anti-pituitary cell antibody, TgAb, TPOAb, and TBII as well as other organ-specific autoantibodies, including glutamic acid decarboxylase autoantibody, insulin autoantibody, gastrin

| Table 1 | Laboratory findings at admission (January 2018) |
|---|---|
| **Hematology** |  |
| Red blood cells | 379 × 10⁶/µl (386–492) |
| Hemoglobin | 113 g/dl (116–148) |
| Hematocrit | 33.7% (35.1–44.4) |
| White blood cells | 3600/µl (3300–8600) |
| Platelets | 20.9 × 10⁹/µl (15.8–34.8) |
| **Blood chemistry** |  |
| Fasting plasma glucose | 65 mg/dl (70–109) |
| Immunoreactive insulin | < 0.2 µU/ml (2.2–12.4) |
| Glycated hemoglobin | 5.2% (4.6–6.2) |
| Total cholesterol | 161 mg/dl (142–248) |
| Triglycerides | 62 mg/dl (30–117) |
| Total protein | 6.2 g/dl (6.6–8.1) |
| Albumin | 3.7 g/dl (4.1–5.1) |
| Aspartate aminotransferase | 31 IU/L (13–30) |
| Alanine aminotransferase | 12 IU/L (7–23) |
| Creatine phosphokinase | 59 IU/L (41–153) |
| Urea nitrogen | 11.4 mg/dl (8.0–18.4) |
| Creatinine | 0.66 mg/dl (0.46–0.79) |
| Uric acid | 2.5 mg/dl (2.6–5.5) |
| Sodium | 124 mEq/L (137–147) |
| Potassium | 4.8 mEq/L (3.5–4.7) |
| Chloride | 90 mEq/L (98–108) |
| Calcium | 8.7 mg/dl (8.8–10.1) |
| C-reactive protein | 0.16 mg/dl (0–0.14) |
| Immunoglobulin G4 | 35 mg/dl (5–117) |
| Carcinoembryonic antigen | 208.0 ng/ml (0–4.76) |
| Sialyl-Lewis X | 2.1 | |
| Squamous cell carcinoma antigen | 1.1 ng/ml (0–1.5) |
| Plasma osmolality | 254 mOsm/L (275–290) |
| Arginine vasopressin | 1.0 pg/ml |
| Thyroid-stimulating hormone | 4.84 µIU/ml (0.50–5.00) |
| Free thyroxine | 1.44 ng/dl (0.90–1.70) |
| Free triiodothyronine | 3.22 pg/ml (2.30–4.00) |
| Adrenocorticotropic hormone | 2.6 pg/ml (7.2–63.3) |
| Serum cortisol | < 0.2 µg/dl (4.5–21.1) |
| Dehydroepiandrosterone sulfate | < 20 ng/ml (120–1330) |
| Plasma renin activity | 0.2 ng/ml/h (0.2–2.3) |
| Aldosterone | 8.8 ng/dl (3.0–15.9) |

The reference range for each parameter is shown in parentheses.

Blood samples were taken in the morning (10 a.m.) with the patient in supine position. The patient was taking thyroid hormone replacement therapy with oral levothyroxine (50 µg/day) for primary hypothyroidism.
The following synthetic hypothalamic hormones were intravenously administered in the morning (9 a.m.): human corticotropin-releasing hormone (CRH; 100 μg), growth hormone-releasing factor (GRF; 100 μg), thyrotropin-releasing hormone (TRH; 500 μg), and luteinizing hormone-releasing hormone (LHRH; 100 μg). The hormone replacement therapy with oral levothyroxine (50 μg/day) for primary hypothyroidism was discontinued on day 2 after admission, and the patient’s serum levels of free thyroxine (1.26 ng/dl) and free triiodothyronine (2.77 pg/ml) were measured just before the drug administration.

parietal cell autoantibody, intrinsic factor autoantibody, adenocortical autoantibody, antinuclear antibody, Sjögren’s syndrome A and B antibodies, anti-citrullinated peptide antibody, and rheumatoid factor.

Human leukocyte antigen (HLA) typing revealed the presence of A*08:01/12:02, B*48:01/52:01, and C*08:01/12:02 class I genes and DRB1*04:05/09:01, DQB1*03:03/04:01, DQA1*03:02/03:03, and DPB1*04:02/14:01 class II genes.

The patient began corticosteroid replacement therapy with oral hydrocortisone (15 mg/day) for AI secondary to IAD on the afternoon of day 8 of admission. Subsequently, she resumed oral levothyroxine (50 μg/day) for primary hypothyroidism on day 9 of admission.

The patient experienced improvements in anorexia, fatigue, and general weakness and became ambulatory within days. Her hyponatremia was corrected within 1 week, and her hypoglycemia was resolved. Laboratory data obtained on day 21 of admission showed normal levels of serum sodium (140 mEq/L), potassium (4.3 mEq/L), chloride (106 mEq/L), FT₄ (1.60 ng/dl), TSH (3.28 μU/ml), and fasting plasma glucose (78 mg/dl). The patient was discharged on day 25 of admission.

The subsequent clinical course of the patient was mostly uneventful for 6 months after discharge. As her LAC progressed, her ability to perform activities of daily living decreased, and in November 2018, she was transferred to a local hospital to receive terminal care.

**Discussion**

Our patient with advanced LAC developed painless thyroiditis associated with a transient elevation of serum thyroid hormones (thyrotoxicosis) during 3 months of second-line chemotherapy with nivolumab and began thyroid hormone replacement therapy for subsequent primary hypothyroidism. Four months after nivolumab therapy was discontinued, the patient developed IAD. Other than reports regarding nivolumab, there have been few reports on thyroid or pituitary dysfunction associated with the anticancer agents that our patient took, including bevacizumab and ramucirumab (Fig. 3) [26–29]. External brain radiotherapy can produce pituitary dysfunction that is usually associated with GH deficiency, but it seldom causes IAD [30]. These findings suggest that our patient exhibited both ICI-related thyroiditis and IAD induced by nivolumab.

Table 5 summarizes the characteristics of reported patients who exhibited nivolumab-related thyroiditis and IAD [15, 16, 19, 20]. The cases describe both male and female adults with melanoma, LAC, or renal cell carcinoma. They developed thyroiditis that resulted in hypothyroidism and subsequently developed IAD.

Thyroiditis is the most frequent IRAE associated with endocrine organs, regardless of the different ICIs [3, 6]. Thyroiditis usually occurs within a few months of initiating ICI therapy with or without verifiable circulating thyroid autoantibodies, such as TgAb and TPOAb. Common clinical manifestations of ICI-related thyroiditis include painless thyroiditis characterized by a transient thyrotoxicosis and subsequent occurrence of persistent primary hypothyroidism [31, 32]. In our patient, physical findings, thyroid gland image findings (Fig. 4), and the clinical course (Fig. 3) indicated that she had a typical form of ICI-related thyroiditis.

Studies on patients with IAD associated with nivolumab have shown that the latency from initial nivolumab administration to IAD onset ranged approximately from 4 to 8 months, with a mean period of roughly 6 months [7–20], which appears to be longer than that of ipilimumab-related hypophysitis (approximately 2 months) [5]. Most cases of nivolumab-related IAD occurred during the course of or within 1 month of the discontinuation of

### Table 3 Endocrinological investigation: CRH/GRF/TRH/LHRH stimulation test in January 2018 (day 7 after admission)

| Time (min) | 0 | 15 | 30 | 60 | 90 | 120 |
|------------|---|----|----|----|----|-----|
| Adrenocorticotropic hormone (pg/ml) | 2.1 | 3.5 | 4.0 | 3.4 | 2.9 | 2.2 |
| Cortisol (μg/dl) | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 |
| Thyroid-stimulating hormone (mIU/ml) | 5.47 | 22.86 | 33.95 | 28.66 | 23.64 | 17.65 |
| Growth hormone (ng/ml) | 7.67 | 19.96 | 34.68 | 38.76 | 37.53 | 21.17 |
| Prolactin (ng/ml) | 22.6 | 75.6 | 94.4 | 84.6 | 61.2 | 44.6 |
| Luteinizing hormone (mIU/ml) | 10.4 | 21.8 | 30.9 | 45.3 | 47.9 | 43.1 |
| Follicle-stimulating hormone (mIU/ml) | 32.8 | 36.2 | 33.6 | 36.6 | 45.6 | 45.5 |

The following synthetic hypothalamic hormones were intravenously administered in the morning (9 a.m.): human corticotropin-releasing hormone (CRH; 100 μg), growth hormone-releasing factor (GRF; 100 μg), thyrotropin-releasing hormone (TRH; 500 μg), and luteinizing hormone-releasing hormone (LHRH; 100 μg).

### Table 4 Endocrinological investigation: GHRP-2 stimulation test in January 2018 (day 8 after admission)

| Time (min) | 0 | 15 | 30 | 45 | 60 |
|------------|---|----|----|----|----|
| Adrenocorticotropic hormone (pg/ml) | 1.9 | 2.3 | 1.9 | 1.9 | 3.2 |
| Cortisol (μg/dl) | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 |
| Growth hormone (ng/ml) | 3.73 | 18.02 | 29.63 | 32.98 | 26.21 |

Growth hormone-releasing peptide (GHRP)-2 (100 μg) was intravenously administered in the morning (9 a.m.)
| Ref. | Age/sex | Nivolumab | Regimen | Administration times (courses) | Time from first nivolumab administration to thyroiditis onset (months) | Thyroid function abnormality | Thyroid autoantibodies | Abnormality on thyroid ultrasonography | Time from first nivolumab administration to IAD onset (months) | Major symptoms | Pituitary autoantibodies | Morphological abnormality in the pituitary on MRI | Other IRAEs |
|------|---------|------------|---------|-------------------------------|-----------------------------------------------------------------|---------------------------|----------------------|---------------------------------|-------------------------------------------------------------|----------------|-----------------------|----------------------------------|-----------|
| [15] | 60/M    | LAC        | 3 mg/kg every 2 weeks | 11 | 5 | Hypothyroidism | N/D | N/D | 7 | Fatigue, anorexia, dizziness, gait instability | N/D | None | None |
| [16] | 54/M    | RCC        | 2 mg/kg every 2 weeks | 12 | 3 | Hypothyroidism | Positive (TgAb and TPOAb) | N/D | 6 | Fatigue, hypoglycemia | N/D | None | None |
| [19] | 58/M    | Melanoma   | 3 mg/kg every 2 weeks | N/D | 4 | Transient thyrotoxicosis and subsequent hypothyroidism | Positive (TgAb) | N/D | 8 | Fatigue, anorexia, weakness | N/D | None | Hypercalcemia |
| [20] | 63/F    | Melanoma   | 2 mg/kg every 3 weeks | 8 | 6 | Transient thyrotoxicosis and subsequent hypothyroidism | Positive (TgAb) | Low echogenicity | 8 | Fatigue | N/D | None | None |
| Present case | 69/F | LAC | 3 mg/kg every 2 weeks | 6 | 2 | Transient thyrotoxicosis and subsequent hypothyroidism | Negative | Low echogenicity | 7 | Fatigue, anorexia, weakness | Negative | Atrophy | None |

F female, IAD isolated adrenocorticotropic hormone deficiency, IRAE immune-related adverse event, LAC lung adenocarcinoma, M male, MRI magnetic resonance imaging, N/D not described, RCC renal cell carcinoma, TgAb thyroglobulin autoantibody, TPOAb thyroid peroxidase autoantibody
nivolumab therapy [7–19], but one patient with melanoma who completed 6 months of nivolumab therapy 2 months prior developed IAD during subsequent ipilimumab therapy [20]. Similarly, our patient with LAC developed IAD 4 months after the discontinuation of 3 months of nivolumab therapy. Our patient’s case highlights the need for physicians to be aware that endocrine IRAEs, including hypophysitis, can occur more than several months after discontinuing a drug.

Patients with ipilimumab-related hypophysitis usually exhibit pituitary enlargement as radiological evidence of pituitary inflammation and pituitary dysfunction with multiple deficits in anterior pituitary hormones [4, 5, 33]. By contrast, many studies of nivolumab-related IAD have reported no morphological pituitary abnormalities [8–17, 19, 20], whereas two studies described patients who showed mild or slight but definitely reversible pituitary enlargement [7, 18]. However, there was a reported case of a patient with atezolizumab-related IAD who showed anterior pituitary atrophy [22]. Similarly, our patient exhibited mild anterior pituitary atrophy (Fig. 5).

Autoimmune polyendocrine syndromes (APS) are a heterogeneous group of endocrine and nonendocrine organ-specific autoimmune disorders [34]. For example, autoimmune thyroid diseases can be associated with other endocrine disorders as part of APS type 3. Genetic factors, including HLA class II genes, play a role in the development of APS. Our patient with ICI-related thyroiditis and IAD had the HLA-DRB1*04:05–DQB1*04:01–DQA1*03:03 and DRB1*09:01–DQB1*03:03–DQA1*03:02 haplotypes, which increase susceptibility to APS type 3 associated with pituitary disorders in the Japanese population [35]. These findings suggest that administration of nivolumab in combination with a genetic predisposition to polyglandular autoimmunity caused thyroiditis and hypophysitis in association with APS type 3, resulting in primary hypothyroidism and IAD, respectively, in our patient.

**Conclusions**

We describe a patient with advanced LAC who developed thyroiditis during 3 months of nivolumab therapy and subsequently exhibited IAD 4 months after the discontinuation of nivolumab. The combination of nivolumab administration and genetic factors that manifested a susceptibility to polyglandular autoimmunity likely caused her ICI-related thyroiditis and hypophysitis. Thus, physicians should be aware that ICI-related endocrinopathies, including hypophysitis, may occur more than several months after discontinuation of the drug.

**Abbreviations**

ACTH: Adrenocorticotropic hormone; AI: Adrenal insufficiency; APS: Autoimmune polyendocrine syndrome; Bmab: Bevacizumab; CDDP: Cisplatin; CRH: Corticotropin-releasing hormone; CT: Computed tomography; DTX: Docetaxel; F: Female; FT4: Free thyroxine; GH: Growth hormone; GHRP: Growth hormone-releasing peptide; GRF: Growth hormone-releasing factor; HLA: Human leukocyte antigen; IAD: Isolated adrenocorticotropic hormone deficiency; ICI: Immune checkpoint inhibitor; IRAE: Immune-related adverse event; LAC: Lung adenocarcinoma; LHRH: Luteinizing hormone-releasing hormone; Ly: Lymph duct; M: Male; MRI: Magnetic resonance imaging; N/D: Not described; PD-1: Anti-programmed cell death protein-1; PD-L1: Anti-programmed cell death ligand-1; PEM: Pemetrexed; RCC: Renal cell carcinoma; RECIST: Response Evaluation Criteria in Solid Tumors; Rmab: Ramucirumab; TBII: Thyroid-stimulating hormone-binding inhibitory immunoglobulin; TgAb: Thyroglobulin autoantibody; TPOAb: Thyroid peroxidase autoantibody; TRH: Thyrotropin-releasing hormone; TSH: Thyroid-stimulating hormone; V: Vein

**Acknowledgements**

The authors thank the clinical laboratory technicians of Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, for their valuable technical support.
Funding
No sources of funding are declared for this study.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
NO, MK, KO, RI, and YI contributed to patient management. NO was a major contributor to the writing of the manuscript. GK, YY, and TT critically reviewed the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was performed in accordance with the Declaration of Helsinki.

Consent for publication
Written informed consent was obtained from the patient for publication of the manuscript.

Consent for publication
This study was performed in accordance with the Declaration of Helsinki.

Funding
No sources of funding are declared for this study.

Ethics approval and consent to participate
This study was performed in accordance with the Declaration of Helsinki.

Consent for publication
Written informed consent was obtained from the patient for publication of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Endocrinology and Metabolism, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, 4132 Utsa, Minamiuonuma, Niigata 949-7302, Japan. 2Department of Diabetes, Endocrinology and Metabolism, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan. 3Department of Respiratory Medicine, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan. 4Department of Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan. 5Department of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.

Received: 6 June 2018 / Accepted: 29 January 2019

Published online: 26 March 2019

References
1. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20:812–22.
2. Michot JM, Bigenwald C, Champliat S, Collins M, Carbonnel F, Postel-Vinay S, Bersetou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fueara A, Ribrag V, Gazzah A, Ohara N, Ohashi K, Fujisaki T, Oda C, Ikeda Y, Yoneoka Y, Hashimoto T, Hasegawa G, Suzuki K, Takada T. Isolated adrenal insufficiency induced by nivolumab in a patient with metastatic melanoma. J Endocrinol Invest. 2015;38:1159–62.
3. Fukuoka H, Ogawa W, Takahashi Y. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2017;2:e000217.
4. Kané K, Ikuchi G, Bando H, Fujita Y, Ōdake Y, Yoshida K, Matsumoto R, Fukushita H, Ogawa W, Takahashi Y. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2017;2:91–5.
5. Andrioli M, Pecori Giraldi F, Cavagnini F. Isolated corticosterone deficiency. Pituitary. 2006;9:289–95.
6. Goldstraw P, Ball D, Jett JR, Le Chevaller T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Daney J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shanks L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:2284–8.
8. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;57:434–6.
30. Kyriakakis N, Lynch J, Orme SM, Gerrard G, Hatfield P, Loughrey C, Short SC, Murray RD. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. Clin Endocrinol. 2016;84:372–9.

31. O’Malley G, Lee HJ, Parekh S, Galsky MD, Smith CB, Friedlander P, Yanagisawa RT, Gallagher EJ. Rapid evolution of thyroid dysfunction in patients treated with nivolumab. Endocr Pract. 2017;23:1223–31.

32. Maekura T, Naito M, Tahara M, Ikegami N, Kimura Y, Sonobe S, Kobayashi T, Tsuji T, Minomo S, Tamiya A, Atagi S. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer. In Vivo. 2017;31:1035–9.

33. Falorni A, Minarelli V, Bartoloni E, Alunno A, Gerli R. Diagnosis and classification of autoimmune hypophysitis. Autoimmun Rev. 2014;13:412–6.

34. Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev. 2014;13:85–9.

35. Hashimoto K, Maruyama H, Nishiyama M, Asaba K, Ikeda Y, Takao T, Iwasaki Y, Kumon Y, Suehito T, Tanimoto N, Mizobuchi M, Nakamura T. Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Horm Res. 2005;64:253–60.